{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:54:14Z","timestamp":1792450454516,"version":"4.5.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>The analytically sensitive detection of KIT D816V in blood and bone marrow is important for diagnosing systemic mastocytosis (SM). Additionally, precise quantification of the KIT D816V variant allele fraction (VAF) is relevant clinically because it helps to predict multilineage involvement and prognosis in cases of advanced SM. Digital PCR (dPCR) is a promising new method for sensitive detection and accurate quantification of somatic mutations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>We performed a validation study of dPCR for KIT D816V on 302 peripheral blood and bone marrow samples from 156 patients with mastocytosis for comparison with melting curve analysis after peptide nucleic acid-mediated PCR clamping (clamp-PCR) and allele-specific quantitative real-time PCR (qPCR).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>dPCR showed a limit of detection of 0.01% VAF with a mean CV of 8.5% and identified the mutation in 90% of patients compared with 70% for clamp-PCR (P &amp;lt; 0.001). Moreover, dPCR for KIT D816V was highly concordant with qPCR without systematic deviation of results, and confirmed the clinical value of KIT D816V VAF measurements. Thus, patients with advanced SM showed a significantly higher KIT D816V VAF (median, 2.43%) compared with patients with indolent SM (median, 0.14%; P &amp;lt; 0.001). Moreover, dPCR confirmed the prognostic significance of a high KIT D816V VAF regarding survival (P &amp;lt; 0.001).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>dPCR for KIT D816V provides a high degree of precision and sensitivity combined with the potential for interlaboratory standardization, which is crucial for the implementation of KIT D816V allele burden measurement. Thus, dPCR is suitable as a new method for KIT D816V testing in patients with mastocytosis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1373\/clinchem.2017.277897","type":"journal-article","created":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T13:25:27Z","timestamp":1513171527000},"page":"547-555","source":"Crossref","is-referenced-by-count":79,"title":["Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis"],"prefix":"10.1093","volume":"64","author":[{"given":"Georg","family":"Greiner","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gurbisz","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Ratzinger","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Witzeneder","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria"},{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Simonitsch-Klupp","sequence":"first","affiliation":[{"name":"Department of Pathology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerlinde","family":"Mitterbauer-Hohendanner","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Mayerhofer","sequence":"first","affiliation":[{"name":"Ludwig Boltzmann Institute of Osteology, Hanusch Hospital, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonhard","family":"M\u00fcllauer","sequence":"first","affiliation":[{"name":"Department of Pathology, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang R","family":"Sperr","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria"},{"name":"Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Valent","sequence":"first","affiliation":[{"name":"Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria"},{"name":"Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Hoermann","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria"},{"name":"Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,3,1]]},"reference":[{"key":"2020022606033477100_B1","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"key":"2020022606033477100_B2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/ehm.10.42","article-title":"Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives","volume":"3","author":"Arock","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"2020022606033477100_B3","first-page":"54","article-title":"Mastocytosis","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Horny","year":"2008","edition":"4th Ed"},{"key":"2020022606033477100_B4","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"2020022606033477100_B5","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"2020022606033477100_B6","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020022606033477100_B7","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-kit catalytic domain mutations in distinct clinical forms of human mastocytosis","volume":"96","author":"Longley","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020022606033477100_B8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1746-1596-2-37","article-title":"Sensitive and reliable detection of kit point mutation asp 816 to val in pathological material","volume":"2","author":"Kahler","year":"2007","journal-title":"Diagn Pathol"},{"key":"2020022606033477100_B9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/jcp.2007.047928","article-title":"Detection of the c-kit d816v mutation in systemic mastocytosis by allele-specific PCR","volume":"61","author":"Schumacher","year":"2008","journal-title":"J Clin Pathol"},{"key":"2020022606033477100_B10","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"2020022606033477100_B11","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/leu.2015.24","article-title":"Kit mutation analysis in mast cell neoplasms: recommendations of the European competence network on mastocytosis","volume":"29","author":"Arock","year":"2015","journal-title":"Leukemia"},{"key":"2020022606033477100_B12","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0002-9440(10)63870-9","article-title":"One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes","volume":"162","author":"Sotlar","year":"2003","journal-title":"Am J Pathol"},{"key":"2020022606033477100_B13","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","article-title":"Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay","volume":"13","author":"Kristensen","year":"2011","journal-title":"J Mol Diagn"},{"key":"2020022606033477100_B14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-013-1964-1","article-title":"The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis","volume":"93","author":"Erben","year":"2014","journal-title":"Ann Hematol"},{"key":"2020022606033477100_B15","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/all.12409","article-title":"The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease","volume":"69","author":"Hoermann","year":"2014","journal-title":"Allergy"},{"key":"2020022606033477100_B16","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/modpathol.2015.72","article-title":"Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications","volume":"28","author":"Jara-Acevedo","year":"2015","journal-title":"Mod Pathol"},{"key":"2020022606033477100_B17","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jaci.2013.02.019","article-title":"KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis","volume":"132","author":"Broesby-Olsen","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"2020022606033477100_B18","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J Clin Oncol"},{"key":"2020022606033477100_B19","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","article-title":"Pkc412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with amn107, imatinib, and cladribine (2cda) and evaluation of cooperative drug effects","volume":"107","author":"Gleixner","year":"2006","journal-title":"Blood"},{"key":"2020022606033477100_B20","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N Engl J Med"},{"key":"2020022606033477100_B21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","article-title":"Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers","volume":"130","author":"Jawhar","year":"2017","journal-title":"Blood"},{"key":"2020022606033477100_B22","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","article-title":"Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia","volume":"20","author":"Branford","year":"2006","journal-title":"Leukemia"},{"key":"2020022606033477100_B23","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/bjh.14557","article-title":"Measurement of BCR-ABL1 by RT-qPCR in chronic myeloid leukaemia: findings from an international EQA programme","volume":"177","author":"Scott","year":"2017","journal-title":"Br J Haematol"},{"key":"2020022606033477100_B24","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1038\/leu.2016.90","article-title":"Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the international scale","volume":"30","author":"Cross","year":"2016","journal-title":"Leukemia"},{"key":"2020022606033477100_B25","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1021\/ac202028g","article-title":"High-throughput droplet digital PCR system for absolute quantitation of DNA copy number","volume":"83","author":"Hindson","year":"2011","journal-title":"Anal Chem"},{"key":"2020022606033477100_B26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1373\/clinchem.2014.221366","article-title":"Considerations for digital PCR as an accurate molecular diagnostic tool","volume":"61","author":"Huggett","year":"2015","journal-title":"Clin Chem"},{"key":"2020022606033477100_B27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2016-09-739003","article-title":"Ccl2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis","volume":"129","author":"Greiner","year":"2017","journal-title":"Blood"},{"key":"2020022606033477100_B28","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/0145-2126(88)90050-1","article-title":"Establishment of an immature mast cell line from a patient with mast cell leukemia","volume":"12","author":"Butterfield","year":"1988","journal-title":"Leuk Res"},{"key":"2020022606033477100_B29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bdq.2017.04.001","article-title":"Methods to determine limit of detection and limit of quantification in quantitative real-time PCR (qPCR)","volume":"12","author":"Forootan","year":"2017","journal-title":"Biomol Detect Quantif"},{"key":"2020022606033477100_B30","article-title":"Guidelines for the single-laboratory validation of qualitative real-time PCR methods","author":"Grohmann","year":"2016"},{"key":"2020022606033477100_B31","article-title":"R: a language and environment for statistical computing","author":"R Development Core Team","year":"2005"},{"key":"2020022606033477100_B32","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1373\/clinchem.2003.029983","article-title":"Partly nonparametric approach for determining the limit of detection","volume":"50","author":"Linnet","year":"2004","journal-title":"Clin Chem"},{"key":"2020022606033477100_B33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1182\/blood.V124.21.4540.4540","article-title":"Exceeding MR5.0 sensitivity in routine BCR-ABL1 analysis using multiplex digital PCR","volume":"124","author":"Andersen","year":"2014","journal-title":"Blood"},{"key":"2020022606033477100_B34","article-title":"Cumulative sum tests: theory and practice","author":"Dobben de Bruyn CSv","year":"1968"},{"key":"2020022606033477100_B35","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/ejh.12601","article-title":"Targeted ultradeep next-generation sequencing as a method for KIT D816V mutation analysis in mastocytosis","volume":"96","author":"Kristensen","year":"2016","journal-title":"Eur J Haematol"},{"key":"2020022606033477100_B36","doi-asserted-by":"crossref","first-page":"12484","DOI":"10.1038\/ncomms12484","article-title":"Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults","volume":"7","author":"Young","year":"2016","journal-title":"Nat Commun"},{"key":"2020022606033477100_B37","doi-asserted-by":"crossref","first-page":"S219","DOI":"10.1007\/s00277-015-2315-1","article-title":"Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization","volume":"94","author":"Cross","year":"2015","journal-title":"Ann Hematol"},{"key":"2020022606033477100_B38","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1515\/cclm-2014-1202","article-title":"Assessing quality and functionality of DNA isolated from FFPE tissues through external quality assessment in tissue banks","volume":"53","author":"Ahmad-Nejad","year":"2015","journal-title":"Clin Chem Lab Med"},{"key":"2020022606033477100_B39","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/1471-2164-16-S13-S1","article-title":"Non-random fragmentation patterns in circulating cell-free DNA reflect epigenetic regulation","volume":"16","author":"Ivanov","year":"2015","journal-title":"BMC Genomics"},{"key":"2020022606033477100_B40","doi-asserted-by":"crossref","first-page":"e77771","DOI":"10.1371\/journal.pone.0077771","article-title":"Improved PCR performance using template DNA from formalin-fixed and paraffin-embedded tissues by overcoming PCR inhibition","volume":"8","author":"Dietrich","year":"2013","journal-title":"PLoS One"}],"container-title":["Clinical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/64\/3\/547\/32642436\/clinchem0547.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/clinchem\/article-pdf\/64\/3\/547\/32642436\/clinchem0547.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T06:10:17Z","timestamp":1582697417000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/clinchem\/article\/64\/3\/547\/5608831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,1]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3,1]]},"published-print":{"date-parts":[[2018,3,1]]}},"URL":"https:\/\/doi.org\/10.1373\/clinchem.2017.277897","relation":{},"ISSN":["0009-9147","1530-8561"],"issn-type":[{"value":"0009-9147","type":"print"},{"value":"1530-8561","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,3,1]]},"published":{"date-parts":[[2018,3,1]]}}}